**TDMS No.** 20310 - 02 **Test Type:** 26-39 WEEKS

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

3'-Azido-3'-deoxythymidine (AIDS) **CAS Number:** 30516-87-1

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:34 First Dose M/F: 11/18/04 / NA

Lab: NCTR

Route: GAVAGE Species/Strain:

MICE/C3B6F1-+/Trp53(tm1Brd)

C Number: C20310C

**Lock Date:** 12/01/2008

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

Study Gender: Male

**TDMSE Version:** 2.1.0

# P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

3'-Azido-3'-deoxythymidine (AIDS)

**CAS Number:** 30516-87-1

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:34 First Dose M/F: 11/18/04 / NA

Lab: NCTR

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

**TDMS No.** 20310 - 02 **Test Type:** 26-39 WEEKS

Route: GAVAGE

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle 6 mo M	AZT 120 6 mo M	Vehicle 9 mo M	AZT 40 9 mo M	AZT 80 9 mo M	AZT 120 9 mo
Disposition Summary						
Animals Initially in Study	27	26	27	27	27	27
Early Deaths Moribund Sacrifice		3	1	1		1
Natural Death		J	1	2		1
Survivors			_	_		
Moribund Sacrifice Natural Death		1 1	1	3		1 2
Terminal Sacrifice	27	1 21	24	21	27	22
Animals Examined Microscopically	27	26	27	27	27	27
LIMENTARY SYSTEM						
Esophagus	(23)	(23)	(27)	(26)	(27)	(27)
Foreign Body	( )	( )	(	1 (4%)	,	` '
Adventitia, Inflammation, Suppurative				1 (4%)		
Adventitia, Necrosis	(26)	(26)	(26)	1 (4%)	(07)	(25)
Gallbladder Mineralization	(26)	(26)	(26)	(25)	(27)	(25) 1 (4%)
Intestine Large, Cecum	(27)	(26)	(26)	(26)	(27)	(25)
Hyperplasia, Lymphoid	3 (11%)	1 (4%)	( - /	2 (8%)	2 (7%)	3 (12%)
Intestine Large, Colon	(27)	(26)	(26)	(26)	(27)	(25)
Epithelium, Hyperplasia	(07)	(00)	(00)	(00)	(07)	1 (4%)
Intestine Large, Rectum	(27)	(26)	(26)	(26)	(27)	(26)
Degeneration, Cystic Hyperplasia, Lymphoid						1 (4%)
Intestine Small, Duodenum	(27)	(26)	(26)	(25)	(27)	(25)
Inflammation, Chronic Active	(=: /	(=3)	(=3)	(=3)	1 (4%)	(=0)
Intestine Small, Jejunum	(27)	(26)	(26)	(25)	(27)	(25)
Liver	(27)	(26)	(26)	(27)	(27)	(27)
Basophilic Focus			1 (4%)	1 (4%)	(5 ((55))	1 (4%)
Cytomegaly			14 (54%)	14 (52%)	13 (48%)	9 (33%)
Eosinophilic Focus Fatty Change		1 (4%)				
Hematopoietic Cell Proliferation		1 (478)	1 (4%)			
Inflammation, Chronic Active			1 (470)			
Mixed Cell Focus						1 (4%)
Necrosis						` '
Tension Lipidosis			3 (12%)			1 (4%)
Vacuolization Cytoplasmic	8 (30%) (0)	4 (15%) (0)	20 (77%) (0)	17 (63%) (2)	23 (85%) (1)	13 (48%) (0)
Mesentery						

a - Number of animals examined microscopically at site and number of animals with lesion

# P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Test Type: 26-39 WEEKS

3'-Azido-3'-deoxythymidine (AIDS) **CAS Number:** 30516-87-1

Route: GAVAGE

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd) Time Report Requested: 16:30:34

First Dose M/F: 11/18/04 / NA

Date Report Requested: 06/29/2009

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle 6 mo M	AZT 120 6 mo M	Vehicle 9 mo M	AZT 40 9 mo M	AZT 80 9 mo M	AZT 120 9 mo M
Pancreas	(27)	(26)	(27)	(27)	(27)	(27)
Cytoplasmic Alteration Inflammation, Chronic Active					1 (4%) 1 (4%)	1 (4%)
Pigmentation					1 (4%)	1 (470)
Acinar Cell, Degeneration Salivary Glands	(27)	(26)	1 (4%) (27)	(26)	(27)	(27)
Infiltration Cellular, Lymphocyte	5 (19%)	(20)	7 (26%)	4 (15%)	2 (7%)	5 (19%)
Stomach, Forestomach	(27)	(26)	(26)	(26)	(27)	(27)
Epithelium, Hyperplasia Epithelium, Hyperplasia, Squamous			1 (4%)	1 (4%)		
Stomach, Glandular	(27)	(26)	(26)	(26)	(27)	(25)
ARDIOVASCULAR SYSTEM						
Blood Vessel	(26)	(25)	(27)	(27)	(27)	(27)
Heart Cardiomyopathy	(27) 2 (7%)	(26)	(27)	(27)	(27)	(27)
Inflammation, Suppurative	2 (1 /0)			1 (4%)		
Polyarteritis			4 (404)	, ,	1 (4%)	
Pericardium, Inflammation, Chronic Active			1 (4%)			
NDOCRINE SYSTEM						
Adrenal Cortex	(27)	(26)	(27)	(27)	(27)	(27)
Accessory Adrenal Cortical Nodule Cyst			1 (4%) 1 (4%)			
Hypertrophy			1 (4%)		1 (4%)	
Subcapsular, Hyperplasia	2 (7%)	2 (8%)	6 (22%)	6 (22%)	7 (26%)	6 (22%)
Adrenal Medulla Islets. Pancreatic	(26) (27)	(24) (26)	(25) (27)	(26) (27)	(24) (27)	(26) (27)
Hyperplasia	(27)	(20)	(27)	(21)	1 (4%)	(21)
Parathyroid Gland	(22)	(23)	(16)	(20)	(21)	(22)
Cyst Pituitary Gland	(27)	(25)	(25)	(27)	(27)	1 (5%)
Thyroid Gland	(27) (26)	(25) (26)	(26)	(27) (27)	(27) (27)	(27) (26)
Ćyst	( - /	1 (4%)	1 (4%)	1 (4%)	( /	( - /
Degeneration				1 (4%)		
Ectopic Thymus Infiltration Cellular, Lymphocyte		1 (4%)		1 (4%)		
Follicular Cell, Hyperplasia		1 (470)			1 (4%)	

**GENERAL BODY SYSTEM** 

a - Number of animals examined microscopically at site and number of animals with lesion

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

3'-Azido-3'-deoxythymidine (AIDS)

**CAS Number:** 30516-87-1

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:34 First Dose M/F: 11/18/04 / NA

Lab: NCTR

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

**TDMS No.** 20310 - 02 **Test Type:** 26-39 WEEKS

Route: GAVAGE

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle 6 mo M	AZT 120 6 mo M	Vehicle 9 mo M	AZT 40 9 mo M	AZT 80 9 mo M	AZT 120 9 mo M
Tissue NOS Mediastinum, Abscess Thoracic, Thrombosis	(0)	(0)	(2) 1 (50%)	(1)	(0)	(1) 1 (100%)
GENITAL SYSTEM						
Coagulating Gland Epididymis Hypospermia Serosa, Inflammation, Chronic Active	(0) (27)	(0) (26)	(0) (27)	(1) (27) 1 (4%)	(0) (27)	(0) (26) 1 (4%)
Serosa, Necrosis Preputial Gland Abscess	(27)	(26)	(27)	(26)	(27)	(26)
Atrophy Degeneration Infiltration Cellular, Lymphocyte Inflammation, Suppurative		1 (4%)	1 (4%)	1 (4%)		3 (12%)
Inflammation, Chronic Active Duct, Dilatation Prostate	(27)	(26)	(27)	1 (4%) (27)	(27)	1 (4%) (25)
Infiltration Cellular, Lymphocyte Inflammation, Suppurative Epithelium, Hyperplasia Seminal Vesicle	(27)	1 (4%) (26)	(26)	(27)	(27)	(26)
Inflammation, Chronic Lumen, Dilatation Serosa, Inflammation, Chronic Active	(21)	1 (4%)	(20)	(21)	(21)	1 (4%)
Testes Spermatocele Interstitial Cell, Hyperplasia	(27)	(26)	(27)	(26) 1 (4%)	(27)	(26)
Seminiferous Tubule, Degeneration		1 (4%)		1 (4%)	1 (4%)	1 (4%)
HEMATOPOIETIC SYSTEM						
Bone Marrow Myeloid Cell, Hyperplasia Lymph Node Lymph Node, Mandibular Hyperplasia, Lymphoid Hyperplasia, Plasma Cell	(27) (0) (26) 1 (4%)	(26) 1 (4%) (1) (26) 1 (4%)	(27) 2 (7%) (0) (27) 1 (4%)	(26) 2 (8%) (1) (25) 1 (4%)	(27) 1 (4%) (0) (27) 1 (4%) 1 (4%)	(26) (1) (26) 2 (8%)
Lymph Node, Mesenteric Hematopoietic Cell Proliferation Hyperplasia, Lymphoid Hyperplasia, Plasma Cell	(27) 19 (70%) 1 (4%)	(25) 16 (64%)	(26) 13 (50%)	(23) 12 (52%)	(26) 17 (65%) 1 (4%)	(25) 1 (4%) 14 (56%)

a - Number of animals examined microscopically at site and number of animals with lesion

Route: GAVAGE

Test Type: 26-39 WEEKS

# P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

3'-Azido-3'-deoxythymidine (AIDS)

-Azido-3-deoxytnymidine (AIDS) **CAS Number:** 30516-87-1

Time Report Requested: 16:30:34 First Dose M/F: 11/18/04 / NA

Date Report Requested: 06/29/2009

1St Dose W/F: 11/16/04 / N/

Lab: NCTR

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle 6 mo M	AZT 120 6 mo M	Vehicle 9 mo M	AZT 40 9 mo M	AZT 80 9 mo M	AZT 120 9 mo N
Infiltration Cellular, Histiocyte					1 (4%)	
Infiltration Cellular, Polymorphonuclear	(07)	(20)	(00)	(0.5)	, ,	1 (4%)
Spleen Depletion Lymphoid	(27)	(26)	(26)	(25)	(27)	(25)
Hematopoietic Cell Proliferation	1 (4%)	2 (8%)	4 (15%)	2 (8%)	5 (19%)	1 (4%)
Hemorrhage Hyperplasia, Lymphoid	2 (7%)		2 (8%)	5 (20%)	6 (22%)	1 (4%) 2 (8%)
Thymus	(26)	(26)	(27)	(24)	(27)	(24)
Atrophy		1 (4%)	1 (4%)		1 (4%)	
Degeneration Hyperplasia, Lymphoid		2 (8%)	1 (4%)	1 (4%)		
Necrosis		2 (6%)	1 (4%)	1 (4%)		
INTEGUMENTARY SYSTEM						
Skin	(27)	(26)	(27)	(27)	(27)	(27)
Abscess					4 (40/)	1 (4%)
Cyst Epithelial Inclusion Hemorrhage					1 (4%)	1 (4%)
MUSCULOSKELETAL SYSTEM						
Bone	(0)	(0)	(1)	(0)	(0)	(0)
Bone, Femur	(27)	(26)	(27)	(27)	(27)	(27)
Skeletal Muscle Diaphragm, Foreign Body	(27)	(26)	(27)	(27) 1 (4%)	(27)	(27)
Diaphragm, Inflammation, Granulomatous				1 (4%)		
NERVOUS SYSTEM						
Brain, Brain Stem	(27)	(26)	(27)	(27)	(27)	(27)
Brain, Cerebellum Hemorrhage	(27)	(26)	(27)	(27)	(27)	(27) 1 (4%)
Brain, Cerebrum	(27)	(26)	(27)	(27)	(27)	(27)
Mineralization	(=. /	(=5)	4 (15%)	1 (4%)	2 (7%)	(=- /
RESPIRATORY SYSTEM						
Lung	(27)	(26)	(27)	(27)	(27)	(27)
Abscess		1 (4%)	4 (40/)			4 (40/)
Congestion Foreign Body			1 (4%)			1 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Test Type: 26-39 WEEKS

3'-Azido-3'-deoxythymidine (AIE

Route: GAVAGE Species/Strain:

MICE/C3B6F1-+/Trp53(tm1Brd)

3'-Azido-3'-deoxythymidine (AIDS) **CAS Number:** 30516-87-1

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:34 First Dose M/F: 11/18/04 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle 6 mo M	AZT 120 6 mo M	Vehicle 9 mo M	AZT 40 9 mo M	AZT 80 9 mo M	AZT 120 9 mo N
Infiltration Cellular, Lymphocyte Infiltration Cellular, Polymorphonuclear Inflammation, Chronic Active Bronchiole, Epithelium, Hyperplasia			1 (4%)	1 (4%)		1 (4%)
Mediastinum, Inflammation, Suppurative Mediastinum, Necrosis Nose Exudate Foreign Body	(27)	(26)	(27) 1 (4%)	1 (4%) 1 (4%) (27)	(27)	(25)
Inflammation, Suppurative	1 (4%)	1 (4%)	1 (4%)			
SPECIAL SENSES SYSTEM						
Eye Harderian Gland Epithelium, Hyperplasia	(27) (27)	(26) (26) 1 (4%)	(26) (27)	(26) (27)	(27) (27)	(25) (27)
URINARY SYSTEM						
Kidney Bacterium Casts Protein	(27)	(26) 1 (4%)	(26)	(27) 1 (4%)	(27)	(26) 1 (4%)
Cyst Infiltration Cellular, Lymphocyte Inflammation, Chronic Active Mineralization	7 (26%)	2 (8%) 1 (4%)	1 (4%) 6 (23%)	1 (4%) 11 (41%)	6 (22%)	4 (15%)
Nephropathy Capsule, Inflammation, Chronic Active		1 (4%)				
Pelvis, Dilatation Pelvis, Inflammation, Chronic Renal Tubule, Regeneration		2 (8%)				1 (4%) 1 (4%)
Transitional Epithelium, Hyperplasia Urinary Bladder Infiltration Cellular, Lymphocyte	1 (4%) (27)	1 (4%) (26)	(27)	(27)	(27)	(26)
Lumen, Dilatation	1 (4%)	2 (8%)		1 (4%)	2 (7%)	2 (8%)

a - Number of animals examined microscopically at site and number of animals with lesion

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

3'-Azido-3'-deoxythymidine (AIDS)

**CAS Number:** 30516-87-1

**Date Report Requested:** 06/29/2009 **Time Report Requested:** 16:30:34

First Dose M/F: 11/18/04 / NA

Lab: NCTR

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

**TDMS No.** 20310 - 02 **Test Type:** 26-39 WEEKS

Route: GAVAGE

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicl PND 1-8 M	AZT 40 PND 1-8 M
<b>Disposition Summary</b>		
Animals Initially in Study Early Deaths	24	25
Moribund Sacrifice		
Natural Death		1
Survivors		•
Moribund Sacrifice	1	2
Natural Death		
Terminal Sacrifice	23	22
Animals Examined Microscopically	24	25
ALIMENTARY SYSTEM		
Esophagus	(24)	(25)
Foreign Body	( <del>-</del> -7)	(=0)
Adventitia, Inflammation, Suppurative		
Adventitia, Necrosis		
Gallbladder	(24)	(24)
Mineralization		
Intestine Large, Cecum	(24)	(24)
Hyperplasia, Lymphoid	3 (13%)	1 (4%)
Intestine Large, Colon	(24)	(24)
Epithelium, Hyperplasia	45.00	45.00
Intestine Large, Rectum	(24)	(24)
Degeneration, Cystic	1 (4%)	
Hyperplasia, Lymphoid	(24)	(24)
Intestine Small, Duodenum Inflammation, Chronic Active	(24)	(24)
Inflammation, Chronic Active Intestine Small, Jejunum	(24)	(24)
Liver	(24) (24)	(24) (25)
Basophilic Focus	(44)	(23)
Cytomegaly	18 (75%)	14 (56%)
Eosinophilic Focus	10 (1070)	1 (4%)
Fatty Change		. (.,.,
Hematopoietic Cell Proliferation		
Inflammation, Chronic Active	1 (4%)	1 (4%)
Mixed Cell Focus		
Necrosis	2 (8%)	1 (4%)
Tension Lipidosis	3 (13%)	2 (8%)
Vacuolization Cytoplasmic	23 (96%)	18 (72%)
Mesentery	(0)	(0)
Fat, Fibrosis		

a - Number of animals examined microscopically at site and number of animals with lesion

**TDMS No.** 20310 - 02 **Test Type:** 26-39 WEEKS

Route: GAVAGE

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

3'-Azido-3'-deoxythymidine (AIDS)

**CAS Number:** 30516-87-1

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:34

First Dose M/F: 11/18/04 / NA

Lab: NCTR

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicl PND 1-8 M	AZT 40 PND 1-8 M
Pancreas Cytoplasmic Alteration Inflammation, Chronic Active Pigmentation	(23) 1 (4%)	(25)
Acinar Cell, Degeneration Salivary Glands Infiltration Cellular, Lymphocyte Stomach, Forestomach Epithelium, Hyperplasia	(24) 8 (33%) (24)	(25) 8 (32%) (25)
Epithelium, Hyperplasia, Squamous Stomach, Glandular	(24)	(24)
CARDIOVASCULAR SYSTEM		
Blood Vessel Heart Cardiomyopathy Inflammation, Suppurative Polyarteritis Pericardium, Inflammation, Chronic Active	(24) (24)	(24) (25)
ENDOCRINE SYSTEM		
Adrenal Cortex Accessory Adrenal Cortical Nodule Cyst	(24)	(25)
Hypertrophy Subcapsular, Hyperplasia Adrenal Medulla	7 (29%) (24)	1 (4%) 7 (28%) (25)
Islets, Pancreatic Hyperplasia	(23) 1 (4%)	(25) 2 (8%)
Parathyroid Gland Cyst Pituitary Gland	(24)	(24)
Thyroid Gland Cyst	(24) (24)	(25) (24) 1 (4%)
Degeneration Ectopic Thymus Infiltration Cellular, Lymphocyte Follicular Cell, Hyperplasia	1 (4%)	

# **GENERAL BODY SYSTEM**

#### TDMS No. 20310 - 02 P03: IN

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

3'-Azido-3'-deoxythymidine (AIDS) **CAS Number:** 30516-87-1

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:34 First Dose M/F: 11/18/04 / NA

Lab: NCTR

Route: GAVAGE Species/Strain:

MICE/C3B6F1-+/Trp53(tm1Brd)

Test Type: 26-39 WEEKS

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicl PND 1-8 M	AZT 40 PND 1-8 M
Tissue NOS Mediastinum, Abscess Thoracic, Thrombosis	(0)	(1)
GENITAL SYSTEM		
Coagulating Gland	(0)	(0)
Epididymis	(24)	(24)
Hypospermia		1 (4%)
Serosa, Inflammation, Chronic Active	1 (4%)	
Serosa, Necrosis	1 (4%)	(0.1)
Preputial Gland	(24)	(24)
Abscess Atrophy		1 (4%)
Degeneration	1 (4%)	
Infiltration Cellular, Lymphocyte	i (4/0)	
Inflammation, Suppurative		
Inflammation, Chronic Active		
Duct, Dilatation		1 (4%)
Prostate	(24)	(25)
Infiltration Cellular, Lymphocyte	1 (4%)	1 (4%)
Inflammation, Suppurative		
Epithelium, Hyperplasia	1 (4%)	(05)
Seminal Vesicle	(24)	(25)
Inflammation, Chronic		
Lumen, Dilatation Serosa, Inflammation, Chronic Active	1 (4%)	
Testes	(24)	(24)
Spermatocele	( <del>4</del> 4)	1 (4%)
Interstitial Cell, Hyperplasia	2 (8%)	4 (17%)
Seminiferous Tubule, Degeneration	2 (8%)	2 (8%)
	()	V/
HEMATOPOIETIC SYSTEM		
Bone Marrow	(24)	(25)
Myeloid Cell, Hyperplasia	(- ·/	2 (8%)
Lymph Node	(0)	(0)
Lymph Node, Mandibular	(24)	(25)
Hyperplasia, Lymphoid		
Hyperplasia, Plasma Cell	(e. :)	(a. t.)
Lymph Node, Mesenteric	(24)	(24)
Hematopoietic Cell Proliferation Hyperplasia, Lymphoid	15 (63%)	12 (50%)
Hyperplasia, Lymphold Hyperplasia, Plasma Cell	10 (00%)	12 (30%)
Trypotpiasia, Fiasina Oth		

a - Number of animals examined microscopically at site and number of animals with lesion

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Test Type: 26-39 WEEKS

3'-Azido-3'-deoxythymidine (AIDS) **CAS Number:** 30516-87-1

Route: GAVAGE Species/Strain:

MICE/C3B6F1-+/Trp53(tm1Brd)

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:34 First Dose M/F: 11/18/04 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicl PND 1-8 M	AZT 40 PND 1-8 M		 	 		
Infiltration Collular Historyta			_				
Infiltration Cellular, Histiocyte Infiltration Cellular, Polymorphonuclear							
Spleen	(24)	(24)					
Depletion Lymphoid	1 (4%)	0 (400()					
Hematopoiétic Cell Proliferation Hemorrhage	2 (8%)	3 (13%)					
Hyperplasia, Lymphoid	5 (21%)	7 (29%)					
Thymus	(23)	(22)					
Atrophy	1 (40/)						
Degeneration Hyperplasia, Lymphoid	1 (4%)	1 (5%)					
Necrosis		1 (5%)					
		. ,					
INTEGUMENTARY SYSTEM							
Skin	(24)	(25)					
Abscess	, ,	, ,					
Cyst Epithelial Inclusion Hemorrhage							
Tiemomaye							
MUSCULOSKELETAL SYSTEM							
Bone	(0)	(0)					
Bone, Femur	(24)	(25)					
Skeletal Muscle	(24)	(25)					
Diaphragm, Foreign Body Diaphragm, Inflammation, Granulomatous							
Diaphiaghi, inilamination, Grandiomatous							
NERVOUS SYSTEM							
Brain, Brain Stem	(24)	(25)					
Brain, Cerebellum	(24)	(25)					
Hemorrhage	(0.4)	(05)					
Brain, Cerebrum Mineralization	(24) 6 (25%)	(25) 3 (12%)					
	0 (2070)	3 (1270)		 	 	 	
RESPIRATORY SYSTEM							
Lung	(24)	(25)					
Abscess	(= ./	(20)					
Congestion		4 (40()					
Foreign Body		1 (4%)					

a - Number of animals examined microscopically at site and number of animals with lesion

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Test Type: 26-39 WEEKS

3'-Azido-3'-deoxythymidine (AIDS) **CAS Number:** 30516-87-1

Route: GAVAGE Species/Strain:

MICE/C3B6F1-+/Trp53(tm1Brd)

Date Report Requested: 06/29/2009 Time Report Requested: 16:30:34 First Dose M/F: 11/18/04 / NA

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicl PND 1-8 M	AZT 40 PND 1-8 M
Infiltration Cellular, Lymphocyte		. (124)
Infiltration Cellular, Polymorphonuclear Inflammation, Chronic Active		1 (4%)
Bronchiole, Epithelium, Hyperplasia Mediastinum, Inflammation, Suppurative		1 (4%)
Mediastinum, Necrosis Nose	(24)	(25)
Exudate	(24)	
Foreign Body Inflammation, Suppurative		1 (4%) 1 (4%)
SPECIAL SENSES SYSTEM		
Eye	(24)	(24)
Harderian Gland Epithelium, Hyperplasia	(24)	(25)
срипенин, пурегразіа 		
URINARY SYSTEM		
Kidney Bacterium	(24)	(25)
Casts Protein		
Cyst Infiltration Cellular, Lymphocyte	6 (25%)	6 (24%)
Inflammation, Chronic Active Mineralization		1 (4%)
Nephropathy Capsule, Inflammation, Chronic Active	1 (4%)	. ,
Pelvis, Dilatation	1 (770)	1 (4%)
Pelvis, Inflammation, Chronic Renal Tubule, Regeneration	2 (8%)	3 (12%)
Transitional Epithelium, Hyperplasia Urinary Bladder	(24)	(24)
Infiltration Cellular, Lymphocyte Lumen, Dilatation	,	1 (4%)

\*\*\* END OF MALE \*\*\*

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion